Avidity Biosciences, Inc. RNA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
50/100
Developing

Ranked against 712 peers in Biotechnology

About Avidity Biosciences, Inc.

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivery of RNA therapeutics to the heart to transform the care for people living with cardiomyopathies. The company offers ATR 1072, is a potentially disease-modifying treatment for PRKAG2 syndrome; ATR 1086 for phospholamban (PLN) cardiomyopathy. The company also provides cardiac disease pipeline, includes PRKAG2 syndrome, PLN cardiomyopathy. The company was formerly known … Full RNA analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.84), suggesting sticky customer base.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.64), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.00), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
35
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where RNA ranks in Biotechnology

Avidity Biosciences, Inc. ranks #243 of 713 scored companies in Biotechnology by moat score — the top 34%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
239 GH Research PLC GHRS 50/100 Moderate
240 DiaMedica Therapeutics Inc. DMAC 50/100 Moderate
241 Biomotion Sciences Warrant SLXNW 50/100 Moderate
242 Bicycle Therapeutics plc BCYC 50/100 Moderate
243 Avidity Biosciences, Inc. RNA 50/100 Developing
244 Silexion Therapeutics Corp SLXN 50/100 Developing
245 Ocular Therapeutix, Inc. OCUL 50/100 Developing
246 Adicet Bio, Inc. ACET 50/100 Developing
247 Cybin Inc. CYBN 50/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How RNA scores on the Corporate Default defenses

Pricing Power

Score 34 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 52 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 70 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 33 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 63 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 59 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding RNA's moat

What is Avidity Biosciences, Inc.'s moat score?

Avidity Biosciences, Inc. (RNA) scores 50 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #243 of 713 scored companies in Biotechnology, the top 34%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (70/100) and its weakest is Capital Efficiency (33/100).

How does Avidity Biosciences, Inc. compare with other Biotechnology companies?

Avidity Biosciences, Inc. ranks #243 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Bicycle Therapeutics plc (BCYC) at 50 just above it and Silexion Therapeutics Corp (SLXN) at 50 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Avidity Biosciences, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Avidity Biosciences, Inc.?

The Corporate Default template measures 6 defenses, and RNA scores: Pricing Power (34), Cost Advantage (52), Customer Stickiness (70), Capital Efficiency (33), Resilience (63), Scale & Market Position (59). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000